Compare Boston Scientific Corporation (BSX) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Mongodb Inc — how do they compare? Boston Scientific Corporation trades at $51.56 (market cap $74.19B), while Mongodb Inc trades at $438.78 (market cap $35.32B). The key difference: Boston Scientific Corporation is far larger — about 2.1× Mongodb Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | MDB | |
|---|---|---|
Market Cap | $74.19B | $35.32B |
Sector | Health | Technology |
52-Week High | $108.14 | $440.25 |
52-Week Low | $42.63 | $204.37 |
Enterprise Value | $86.27B | $32.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.
The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.
MDB trades at $436.91, up 4.86% over the past day, with a bullish technical signal from moving averages and strong analyst sentiment. Revenue growth is robust, reaching $2.01B in 2025, though the company remains unprofitable with a net income margin of -1.12%. Recent earnings beats and an upcoming Q2 2026 report on September 1, 2026, highlight operational momentum amid high institutional interest.
The outlook is positive given consistent earnings outperformance and projected revenue growth to $2.6B in 2026. Risks include persistent losses, competitive pressures, and high valuation multiples. With 82% of analysts rating it a buy and a consensus price target of $404.30, the stock offers growth potential but requires monitoring of profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
